[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Research Institute for Physical Chemical Problems of the Belarusian State University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100533945","phase-2-clinical-study-in-adult-patients-with-purulent-inflammatory-processes-of-the-skin-and-soft-tissues-phase-i-ii-of-the-wound-process-100533945",false,"NCT06232421","Clinical Study in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues, Phase I-II of the Wound Process","A Prospective, Parallel, Single-blind Clinical Study Using Stratified Randomization of the Effectiveness, Tolerability and Safety of the Medicinal Product \"Foscelantan, Medicinal Plate 4.0x5.0 cm in Package No. 1\" Produced by UNITEKHPROM BSU, Republic of Belarus, in Comparison With the Medicinal Product Povidone- Iodine Produced by BelAseptika JSC, in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues Due to the Neuropathic Form of Diabetic Foot Syndrome or Chronic Venous Insufficiency, Phase I-II of the Wound Process","OLENKRON-01","Inclusion Criteria:\n\n* The presence of purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome (Main diagnosis: Diabetes mellitus type I or II, clinical metabolic compensation\u002Fsubcompensation, class I - II according to the Wagner classification) or chronic venous insufficiency (Main diagnosis: Varicose veins dilatation of the veins of the lower extremities, class C6 according to the CEAP classification), phase I-II of the wound process\n* The size of the ulcerative defect is from 1 cm² to 20 cm²\n* Secondary type of wound healing\n* Absence of exposed bones and tendons in the wound\n* Absence of severe concomitant diseases in the stage of decompensation, oncological diseases, as well as diseases requiring steroid therapy\n* Availability of written informed consent from the patient to participate in the study\n* The patient's ability to follow the instructions of the research physician and comply with the study regimen\n\nExclusion Criteria:\n\n* Individual intolerance or hypersensitivity reactions to the components of the drug Foscelantan\n* Neuroischemic form of diabetic foot syndrome\n* The presence of serious concomitant pathology (severe form of renal and hepatic failure, systemic connective tissue diseases, severe cardiovascular insufficiency), history and current mental illness\n* The need to constantly take drugs from the list of prohibited therapies\n* Participation of the patient in another clinical trial within 3 months before the current clinical trial\n* Acute bleeding\n* Level of peripheral blood leukocytes less than 1.5 × 109 per l, platelets less than 75.0 × 109 per l.\n* Hemoglobin less than 80g per l.\n* Positive tests for syphilis, human immunodeficiency virus (HIV), hepatitis B, or hepatitis C\n* Severe liver dysfunction - AST or ALT levels exceed the upper limit of normal by 5 times or more, bilirubin ≥ 2.0 mg\u002FdL (34.2 µmol\u002FL).\n* Severe renal dysfunction - creatinine 2 times higher than reference values\n* Diabetes mellitus in a state of clinical and metabolic decompensation\n* Pregnant and breastfeeding women\n* At one\\'s own request without explaining the reasons for the action.\n* At the request of the research physician, if the research subject violates the protocol requirements for diet, consumption of alcoholic beverages, and medications without the prescription of the research physician.\n* For reasons independent of the study subject and the research physician, when a study subject develops drug intolerance and other life-threatening or requiring emergency pharmacotherapy adverse reactions to the administration of the study drug.\n* The need to prescribe drugs from the list of prohibited treatments.","ALL","18 Years","70 Years",{"count":21,"type":22},224,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","The purpose of this study is to estimate efficiency, tolerance, safety of \"Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1\" among adult patients who have purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome or chronic venous insufficiency, phase I-II of the wound process.",[29,30],"Diabetic Foot Infections","Chronic Venous Insufficiency",[32,33,34,35,36],"diabetic foot infection","chronic venous insuffiency","lidocaine","cellulose","miramistin","NOT_YET_RECRUITING","2025-07-22",{"date":40,"type":41},"2025-07-25","ACTUAL",{"date":43,"type":22},"2025-11",{"date":45,"type":22},"2026-05",{"name":47,"class":48},"Research Institute for Physical Chemical Problems of the Belarusian State University","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100533946","phase-2-an-open-prospective-randomized-clinical-study-of-the-effectiveness-tolerability-and-safety-of-a-single-intraperitoneal-use-of-the-drug-prospidelong-powder-for-the-preparation-of-a-gel-for-topical-use-1000-mg-in-vials-package-no-1-in-patients-with-disseminated-gastric-cancer-phase-i-ii-100533946","NCT06232434","An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug \"Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1\" in Patients With Disseminated Gastric Cancer, Phase I-II","ИНТЕЛОН-02","Inclusion Criteria:\n\n* Gastric cancer without transition to the esophagus with peritoneal dissemination sT1-4N0-3M1.\n* Life expectancy of at least 6 months\n* Physical status on the ECOG scale 0 - 1.\n* The age of patients is from 18 to 75 years.\n* Absence of severe concomitant diseases in the decompensation stage.\n* Availability of written informed consent from the patient to participate in the study.\n* The ability of the patient and the personnel caring for him to comply with the instructions of the research physician and comply with the study design.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n* The presence of a primary multiple (synchronous or metachronous) malignant tumor. The exception is for patients who were treated for basal cell or squamous cell skin cancer, cervical cancer in situ, or other tumors more than 5 years ago and are expected to be completely cured.\n* Presence of severe concomitant diseases in the stage of decompensation;\n* Family relationships between the patient and the center staff.\n* Allergy to components of the study drug.\n* Refusal of the patient from the proposed treatment method.\n* Presence of heart disease class III or IV according to the New York Heart Association classification or a history of myocardial infarction within 6 months before the 1st day of the study.\n* Any history of epileptic seizures.\n* Severe diseases, including those with severe symptoms, untreated inflammatory and infectious processes, due to which the patient cannot receive treatment in accordance with the study protocol.\n* Chronic liver and\u002For kidney failure.\n* Legal incapacity or other circumstances due to which the patient or his immediate family are unable to understand the nature, scope and possible consequences of the treatment being carried out\n* Socioeconomic or geographic circumstances that cannot guarantee adequate compliance with protocol requirements for treatment and follow-up.\n* History of abuse of alcohol or any chemical substances for 2 years up to the 10th day before the start of the study.\n* Patient participation in another clinical trial.\n\nNon-inclusion criteria based on survey data:\n\n* Acute bleeding from the tumor.\n* Level of peripheral blood leukocytes less than 1.5 × 109 per l, platelets less than 75.0 × 109 per l.\n* Hemoglobin less than 80g per l.\n* Positive tests for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.\n* Severe liver dysfunction - AST and ALT levels exceed the upper limit of normal by 5 times or more, bilirubin greater than or equal to 2.0 mg per dL (34.2 µmol per L).\n* Severe renal impairment - creatinine clearance less than 30 ml per minute, calculated using the Cockcroft-Gault formula - or the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula.\n* Diabetes mellitus in a state of clinical and metabolic decompensation.\n\nCriteria for exclusion (dropout) from the study:\n\n* Individual intolerance to drugs included in the treatment regimen.\n* The patient's desire to stop participating in the study.\n* Serious adverse events occurring in the patient during the study.\n* Violation by the patient of the research conditions of the investigational medicinal product (non-compliance).\n* Pregnancy.\n* Detection of a second malignant tumor","75 Years",{"count":58,"type":22},120,[25,26],"It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg (2000 mg in terms of prospidium chloride) in patients with disseminated gastric cancer.\n\nIn total, the study plans to include 120 patients aged 18 to 75 years inclusive, including 60 patients in the study group and 60 in the comparison group. The study consists of daily examination of patients throughout the entire period of hospitalization and subsequent visits.",[62],"Gastric Cancer With Peritoneal Dissemination",[64,65,66],"gastric cancer with peritoneal dissemination","prospidin","dextran phosphate","RECRUITING","2025-06-20",{"date":70,"type":41},"2025-06-22",{"date":68,"type":41},{"date":73,"type":22},"2025-12",{"name":47,"class":48},1,""]